Recombinant activated factor VII and epsilon aminocaproic acid treatment of a patient with Glanzmann's thrombasthenia for nasal polipectomy.
Gunaydin
Berrin
B
Ozkose
Zerrin
Z
Pezek
Seyda
S
D000328:Adult; D015119:Aminocaproic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D000768:Anesthesia, General / Q000379:methods; D000933:Antifibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control; D004359:Drug Therapy, Combination; D005167:Factor VII / Q000009:adverse effects / Q000627:therapeutic use*; D015942:Factor VIIa; D006801:Humans; D008297:Male; D009298:Nasal Polyps / Q000601:surgery*; D017713:Platelet Transfusion / Q000379:methods; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013915:Thrombasthenia / Q000150:complications* / Q000628:therapy*; D014148:Tranexamic Acid / Q000009:adverse effects / Q000627:therapeutic use
D000933:Antifibrinolytic Agents; D011994:Recombinant Proteins; D014148:Tranexamic Acid; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa; D015119:Aminocaproic Acid